State ordering guide
Sourcing Exosomes in Nevada
Licensed Nevada practices order Kimera exosome material from ExaVeyra as research-grade product, shipped cold-chain from Miami Beach with a Certificate of Analysis and lot traceability on every vial. Nevada buyers need their own professional license and NPI; the wholesale license is the supplier’s obligation, not the purchaser’s.
Nevada deserves a closer read than most states. Its statute reaches biological products rather than only cells and tissues, which has led to a good deal of loose commentary about what is permitted here. The detail that matters is where that statute draws its boundaries. (Tennessee goes further still and names exosomes outright, which no other state does.)
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Nevada? | Yes. Cold-chain from Miami Beach, as we do to all 50 states |
| Cold-chain transit from Miami | 1 to 3 business days |
| State regenerative-medicine statute | AB 188 (2023) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the wholesale distribution permit | The supplier, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material and 503A compounded preparations |
| Last reviewed | 9 August 2026 |
Ordering from Nevada
ExaVeyra ships to licensed practices in all 50 states, Nevada included. Distribution-side licensing is handled by us, so your practice orders against its own professional license and NPI. What varies state to state is not whether product can reach you, but the indications it may be used for under federal law and how Nevada regulates who performs the procedure.
What your practice provides
- An active Nevada professional license in good standing, verifiable through the Nevada State Board of Medical Examiners or the Nevada State Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed research-use acknowledgment on file for exosome material.
- A Nevada resale certificate if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Nevada licenses wholesale distribution through the State Board of Pharmacy. NRS 639.233 reaches any person engaging in wholesale distribution, or furnishing controlled substances, poisons, drugs, devices, or appliances that federal law restricts to sale on a physician’s order, to anyone located in the state. A distributor counts as furnishing if it solicits or accepts orders, or receives, stores, or ships those items. Devices are inside the definition, as in California, New York, and Arizona. The license sits with the distributor, not with the purchasing practice.
NRS 639.233; NAC 639.702 to 639.7093 · Nevada State Board of Pharmacy
Nevada regenerative-medicine law
Nevada enacted AB 188, codified at NRS 630.3735 (physicians); NRS 633.6945 (osteopathic physicians), effective 1 October 2023.
Physicians licensed under chapter 630 and osteopathic physicians licensed under chapter 633. The statute sets consent-form and patient-information requirements, obliges the physician to notify the board of a patient death or hospitalization, requires a biennial report to the Legislature, and provides that acting within its terms is not itself grounds for discipline. Manufacturers supplying under it maintain a hotline for patients who develop adverse effects. Both sections are written to expire on 30 June 2027 unless the Legislature extends them.
- Individualized investigational treatments produced for one patient
- Investigational products for life-threatening or severely debilitating conditions
- Physician consent and reporting duties
- Sunsets 30 June 2027 unless extended
“a drug, biological product or device that is unique to and produced exclusively for use by an individual patient based on the genetic profile of the patient”
How this applies to exosomes
Nevada is often described as having legalised unapproved biologics, so it is worth being precise. Assembly Bill 188 does reach biological products, which is broader than the cells-and-tissues framing used in Florida, Texas, and California. Its gates are narrow, though. The statute addresses an individualized investigational treatment, which it defines as a drug, biological product, or device unique to and produced exclusively for one patient based on that patient’s genetic profile, and it otherwise operates on a right-to-try footing for life-threatening or severely debilitating conditions. A Kimera preparation is allogeneic and made to a lot rather than to a patient’s genome, and topical aesthetic use is not a life-threatening condition, so neither gate is engaged. Exosome products remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use in clinics and for research applications, with full COA and lot documentation.
Who can handle product in a Nevada practice
A designated medical director and a documented examination before treatment are the two things Nevada practices are most consistently expected to have in place. Because the availability standard for a delegating physician is set by board interpretation rather than by a single statutory sentence, it is worth confirming directly with the Board of Medical Examiners rather than relying on secondary summaries.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed under chapter 630, and osteopathic physicians under chapter 633, may perform medical acts within their scope and are the source of any delegation. Chapter 630 also treats practising experimental medicine without patient consent as a ground for discipline, which is worth reading alongside the AB 188 consent requirements. |
| NP / APRN | Advanced practice registered nurses practice within the scope the Nevada State Board of Nursing establishes. Ownership of a practice delivering medical services is a separate question from clinical scope, and is governed by the corporate practice rules rather than by the Nurse Practice Act. |
| PA | Physician assistants practice under physician supervision within the delegated scope. |
| RN | Registered nurses may perform delegated treatments within their scope and under physician delegation. Nevada expects the delegating physician to remain readily available to the treatment site rather than merely on record, so confirm the current availability standard with the Board of Medical Examiners before setting protocols. |
Good faith examination
Nevada expects an examination establishing the practitioner-patient relationship before treatment is delivered, with a designated medical director available to the practice. Where a treatment falls under the AB 188 framework, the statute layers its own written consent form and patient information requirements on top of that.
Ownership and clinic licensing
Nevada recognises the corporate practice of medicine doctrine and the State Board of Medical Examiners is an active enforcer of it, while management services arrangements between a non-physician entity and a clinical practice are widely used. The practical effect is a middle position: less codified than Texas or New York, but not the open field Arizona’s case-law-only posture suggests. Confirm your structure with Nevada counsel before opening.
Cold chain into Nevada
Shipments dispatch from our Miami Beach facility under validated temperature monitoring, and delivery into Nevada is scheduled to avoid a weekend hold at the carrier hub.
| Metro | County | Notes |
|---|---|---|
| Las Vegas | Clark | Largest Nevada market, with heavy aesthetic and concierge concentration. |
| Henderson | Clark | Affluent suburban market adjoining Las Vegas. |
| Reno | Washoe | Northern Nevada hub with a growing longevity segment. |
| Summerlin | Clark | Dense med spa corridor on the west side of the valley. |
| Sparks | Washoe | Served alongside Reno. |
| Carson City | State capital, smaller practice base. |
- Nevada orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Inspect the temperature indicator on arrival and contact us before use if the shipment reads outside range.
- Storage and handling conditions for each product are stated on its Certificate of Analysis.
Practice types we supply in Nevada
Nevada licensing and verification
Nevada State Board of Medical Examiners
Physician license verification and the active enforcer of corporate practice limits.
Nevada State Board of Nursing
Nevada State Board of Pharmacy
Issues the wholesaler license held by out-of-state suppliers.
Nevada Department of Taxation
Where a practice registers before issuing a resale certificate.
Nevada sourcing questions
- Did Nevada legalise unapproved biologics?
- Not in the broad sense that phrase suggests. Assembly Bill 188 (2023) added NRS 630.3735 and NRS 633.6945, which authorise a physician to prescribe or recommend an individualized investigational treatment, defined as a drug, biological product, or device unique to and produced exclusively for one patient based on that patient’s genetic profile, and which otherwise operate on a right-to-try footing for life-threatening or severely debilitating conditions. Both sections are written to expire on 30 June 2027 unless extended.
- Does AB 188 cover exosome products?
- It does not reach an off-the-shelf preparation. The statute’s definition turns on a product made exclusively for one patient from that patient’s genetic profile, and its alternative pathway addresses life-threatening or severely debilitating conditions. A Kimera preparation is allogeneic and manufactured to a lot rather than to an individual genome, and topical aesthetic use is not a qualifying condition. Exosome products remain governed by federal law, and no exosome product is FDA-approved for administration to humans.
- Does my Nevada clinic need a wholesaler license to buy exosomes?
- No. The wholesaler license under NRS 639.233 is held by the distributor furnishing product into Nevada, not by the practice buying. Your practice orders against its own professional license and NPI. ExaVeyra handles distribution-side licensing.
- Does Nevada enforce the corporate practice of medicine?
- Yes, and the State Board of Medical Examiners is an active enforcer, while management services arrangements between a non-physician entity and a clinical practice are widely used. Nevada sits between the codified regimes in Texas and New York and Arizona’s case-law-only posture. Confirm your structure with Nevada counsel.
- What does Nevada expect before a treatment is delivered?
- An examination establishing the practitioner-patient relationship, a designated medical director available to the practice, and a delegating physician who remains readily available to the treatment site. Because the availability standard comes from board interpretation rather than a single statutory sentence, confirm it directly with the Board of Medical Examiners.
- How long does cold-chain shipping take to Nevada?
- Overnight from our Miami Beach facility once prepared, with preparation taking one to two business days. All exosome shipments travel cold-chain with validated temperature monitoring, and deliveries are scheduled to avoid a weekend hold at the carrier hub.
Material available to licensed Nevada practices
Kimera Labs preparations distributed by ExaVeyra, characterised on the certificate of analysis supplied with every lot. Research-grade material for licensed practices; the practitioner determines clinical use.
- Luxir
1 Trillion Microvesicles · 5 Trillion Microvesicles
Available formats: 1.0 mL, 5.0 mL
- Luxir+
3 Trillion Microvesicles · 15 Trillion Microvesicles
Available formats: 1.0 mL, 5.0 mL
- Kiara
3 mg secretome · 15 mg secretome
Available formats: 1.0 mL, 5.0 mL
- Vive
2 Trillion Microvesicles
Available formats: 5.0 mL
Sources
Last reviewed 9 August 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- NRS ch. 630, Physicians (incl. § 630.3735, individualized investigational treatment) (accessed 8 August 2026)
- NRS ch. 639, Pharmacists and Pharmacy (incl. § 639.233) (accessed 8 August 2026)
- NAC ch. 639, wholesaler rules (accessed 8 August 2026)
- Nevada State Board of Medical Examiners (accessed 8 August 2026)
- Nevada State Board of Pharmacy (accessed 8 August 2026)
- Nevada Department of Taxation (accessed 8 August 2026)
- FDA Public Safety Notification on Exosome Products (accessed 8 August 2026)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research applications, and are not tissue products as defined by FDA guidelines.
Reference only. Not legal or medical advice.
The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Read the full disclaimer
ExaVeyra Sciences publishes these guides as a reference for licensed practitioners. They summarize publicly available federal and state requirements as those requirements read on the review date shown above. The content is provided for general informational purposes only and does not constitute legal, medical, or regulatory advice, and it does not establish that any particular product or practice is compliant.
No attorney-client relationship, and no professional or clinical relationship of any kind, is created by accessing these materials. ExaVeyra Sciences is a supplier of research-use materials. It is not a law firm, it is not a regulatory consultant, and it takes no part in any diagnosis, treatment decision, or plan of care. Each practitioner is responsible for retaining their own legal counsel and for determining, with that counsel and the applicable state licensing boards, how the requirements described here apply to the services, staffing, and structure of their own practice.
Statutes, regulations, board rules, and agency positions are subject to amendment, supersession, and reinterpretation. ExaVeyra Sciences makes no representation or warranty as to the accuracy, completeness, timeliness, or applicability of this content to any particular practice. Citations and links to third-party sources are provided for convenience only and do not constitute an endorsement of their content.
The practitioner and the practice are solely responsible for compliance with all applicable licensing, scope of practice, supervision, ownership, facility, recordkeeping, and tax requirements, and for all clinical decisions, including the suitability of any material for a given patient. To the fullest extent permitted by law, ExaVeyra Sciences disclaims all liability for any action taken or not taken in reliance on this content.